The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer

por Stotz, M, Pichler, M, Absenger, G, Szkandera, J, Arminger, F, Schaberl-Moser, R, Samonigg, H, Stojakovic, T, Gerger, A
Publicado 2014

A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients

por Absenger, G, Szkandera, J, Pichler, M, Stotz, M, Arminger, F, Weissmueller, M, Schaberl-Moser, R, Samonigg, H, Stojakovic, T, Gerger, A
Publicado 2013

A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer

por Schippinger, W, Jagoditsch, M, Sorré, C, Gnant, M, Steger, G, Hausmaninger, H, Mlineritsch, B, Schaberl-Moser, R, Mischinger, H J, Hofbauer, F, Holzberger, P, Mittlböck, M, Jakesz, R
Publicado 2005

LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy

por Szkandera, J, Herzog, S, Pichler, M, Stiegelbauer, V, Stotz, M, Schaberl-Moser, R, Samonigg, H, Asslaber, M, Lax, S, Leitner, G, Renner, W, Lenz, H-J, Berghold, A, Gerger, A
Publicado 2015

Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients

por Szkandera, J, Stotz, M, Absenger, G, Stojakovic, T, Samonigg, H, Kornprat, P, Schaberl-Moser, R, AlZoughbi, W, Lackner, C, Ress, A L, Seggewies, F S, Gerger, A, Hoefler, G, Pichler, M
Publicado 2014

A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer

por Schippinger, W, Samonigg, H, Schaberl-Moser, R, Greil, R, Thödtmann, R, Tschmelitsch, J, Jagoditsch, M, Steger, G G, Jakesz, R, Herbst, F, Hofbauer, F, Rabl, H, Wohlmuth, P, Gnant, M, Thaler, J
Publicado 2007